Impact of R&D Intensity on Market Capitalization

Article Sidebar

Download PDF
Published: 2016-06-11
Authors

Preeti Bansal

Dr Manju Gupta

Dr Tripta Garg

DOI: https://doi.org/10.65301/aimt.2016.6.II.677
Keywords:
R&D intensity, Tobin's q, Market capitalization

Issue

Vol. 6 No. II (2016): June - Dec

Section

Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

##plugins.themes.bootstrap3.article.main##

Abstract

The present study is an attempt to assess the impact of Research & Development (R&D) intensity, profit margin and firm size on market valuation of firm proxied by Tobin's q with special reference to pharmaceutical sector. The pharmaceutical industry has been chosen due to intensive research and development expenditures. There are many pharmaceutical companies listed on the BSE and NSE but 25 companies have been chosen at random and analyzed for a period of 10 years from 2005 to 2014 through regression technique. Theoretically, it sounds true that when a company invests in R&D, it increases the probability of innovation and thereby improved growth prospects which reflects in the market capitalization. An attempt has been made to test this hypothesis and much to our surprise, this assumption does not hold true in case of pharmaceutical sector. 

##plugins.themes.bootstrap3.article.details##

References

1. Ballardini, F., Malipiero, A., Oriani, R., Sobrero, M., & Zammit, A. (2005). Do stock markets value innovation? A meta-analysis. A Meta-analysis (January 2005).

2. Ben-Zion, U., & Kim, M. (1984). The effect of ownership on market value and risk of R&D intensive firms. Economics Letters, 16(3), 363-367.

3. Bublitz, B., & Ettredge, M. (1989). The information in discretionary outlays: Advertising, research, and development. Accounting Review, 108-124.

4. Cazavan-Jeny, A., & Jeanjean, T. (2006). The negative impact of R&D capitalization: A value relevance approach. European Accounting Review,15(1), 37-61.

5. Chauvin, K. W., & Hirschey, M. (1993). Advertising, R&D expenditures and the market value of the firm. Financial management, 128-140.

6. Chung, K. H., Wright, P., & Kedia, B. (2003). Corporate governance and market valuation of capital and R&D investments. Review of Financial Economics, 12(2), 161-172.

7. Cockburn, I., & Griliches, Z. (1988). The estimation and measurement of spill over effects of R&D investment-industry effects and appropriability measures in the stock market's valuation of R&D and patents. The American Economic Review, 78(2), 419-423.

8. Duqi, A., & Torluccio, G. (2011). Can R&D expenditures affect firm market value An empirical analysis of a panel of European listed firms. In Bank Performance, Risk and Firm Financing (pp. 215-241). Palgrave Macmillan UK.

9. Hall, B. H. (1993). The stock market's valuation of R&D investment during the 1980's. The American Economic Review, 83(2), 259-264.

10. Hall, B. H., & Oriani, R. (2006). Does the market value R&D investment by European firms Evidence from a panel of manufacturing firms in France, Germany, and Italy. International Journal of Industrial Organization, 24(5), 971-993.

11. Haugen, R. A., & Baker, N. L. (1996). Commonality in the determinants of expected stock returns .Journal of Financial Economics, 41(3), 401-439

12. Hirschey, M.(1982).Intangible capital aspects of advertising and R&D expenditures. The Journal of industrial economics, 375-390.

13. Hirschey, M., & Weygandt, J. J. (1985). Amortization policy for advertising and research and development expenditures. Journal of Accounting Research, 326-335.

14. Jaruzelski, B., Dehoff, K., & Bordia, R. (2005). Money Isn't Everything Lavish R&D budgets don't guarantee success. The Booz Allen Hamilton Global Innovation 1000 tracked the world's heaviest innovation spenders against common measures of performance and success. Strategy and Business, 41, 54.

15. Mullin, R. (2014, November 24). Cost to Develop New Pharmaceutical Drug Now Exceeds $2.5B. Scientific American. Retrieved from: http://www.scientificamerican.com/article/cost-to-develop-new-pharmaceutical-drug-now-exceeds-2-5b/

16. Munari, F., & Oriani, R. (2002). Privatization and R&D Performance: An Empirical Analysis Based on Tobin's q.

17. Schumpeter,J.A.(1942).Socialism, capitalism and democracy. Harper and Brothers.

18. Xu, M., & Zhang, C. (2004). The explanatory power of R&D for the cross-section of stock returns: Japan 1985–2000. Pacific-Basin Finance Journal,12(3), 245-269.